Tirzepatide → Diarrhoea — Null result

← All findings ⬇ Download signed audit packet

Ledger entry · null-result

Tirzepatide → Diarrhoea — Null result

Drug: tirzepatide · AE: Diarrhoea

Caliper validation of the submitted claim (drug=tirzepatide, AE=Diarrhoea). BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.70, lower CI=1.61)

Disproportionality

PRR: 1.6959033106193178 (95% CI 1.61–1.79)
Yates χ²: 407.9357060657337
Cases (case-drug + AE): n = 1389
Verdict: BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=1.70, lower CI=1.61)

Top reactions in cohort

MedDRA PT	n
Diarrhoea	1351
Nausea	496
Vomiting	369
Off label use	201
Eructation	178
Abdominal pain upper	160
Constipation	129
Decreased appetite	105

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 51d40b4fa8a85a99fd66bf46af0815fb8a7aa1c2